NuvOx Closed Oversubscribed Convertible Notes

The latest from NuvOx
- Aug 30
NuvOx Announces Publication of Research Article in Cancer Research Communication
- Aug 14
NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada
- Jun 7
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
- Apr 19
NuvOx Receives SPAN Grant

- Mar 5
NuvOx Newly Issued US Patent


- Oct 11, 2022
- May 19, 2022
NuvOx Pharma Announces Issuance of a New Patent
- May 9, 2022
NuvOx Appoints Dr. Robert King to SAB
- May 9, 2022
NuvOx Technology Featured in Prominent Peer Review Journal
- May 9, 2022
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
- Mar 4, 2022
NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program
- Feb 9, 2022
NuvOx to Participate in the BIO CEO Investor Conference
- Jan 12, 2022
NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022
- Oct 15, 2021
NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke
- Sep 9, 2021
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy
- Jul 29, 2021
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM
- Jul 23, 2021
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer


- May 27, 2021
Tucson's NuvOx adds plant to make drugs in-house
- Apr 30, 2021
NuvOx Completes Construction of Expanded Manufacturing Facility